Clinical trials: Polycystic Kidney Diseases
PCOS, Infertility, Female
Effect of Acupuncture Plus Governor Vessel Moxibustion Combined With Letrozole on Live Birth in Anovulatory Infertile Women With Spleen-kidney Yang Deficiency PCOS
Investigators expected to verify this hypothesis through this study:acupuncture and moxibustion combined with LE induced ovulation in Chinese anovulatory PCOS women has a higher rate of live birth than LE induced ovulation alone.
- Trial name
- PCOS (NCT04987632)
- Testing
- Letrozole, acupuncture, Governor vessel moxibustion
- Volunteers
- 90 people
- Sponsor
- Qiu-ping Lin
ADPKD
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping
This is a retrospective analysis to include demographic, clinical, biochemical, and genetic data that will further explore the natural history of ADPKD and assess the factors that are likely to be associated with the progression…
- Trial name
- ADPKD (NCT02161068)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- The Rogosin Institute
Autosomal Dominant Polycystic Kidney
Treatment of Vascular Stiffness in ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease characterized by cystic kidneys and caused by mutations in the polycystic kidney disease and other rare genes.
- Trial name
- TRAMPOLINE (NCT05228574)
- Testing
- Sodium chloride (NaCl), Amiloride Hcl 5mg Tab
- Where
- Netherlands
- Volunteers
- 46 people
- Sponsor
- Erasmus Medical Center
Autosomal Dominant Polycystic Kidney Disease
Managing Depressive Symptoms in ADPKD
The purpose of this research is to evaluate the feasibility and effectiveness of Digital Neurotherapy (DNT) or Capacity Coaching (CC) for managing symptoms of depression and self reported pain in Autosomal Dominant Polycystic…
- Trial name
- NCT07745920
- Testing
- Mayo Clinic-Approved Education, Digital Neuropathy, Capacity Coaching
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mayo Clinic
Kidney, Polycystic
HALT Progression of Polycystic Kidney Disease Study A
The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and on the decline in renal function in autosomal dominant kidney disease (ADPKD) will be assessed in two…
- Trial name
- HALT PKD A (NCT00283686)
- Testing
- Lisinopril, Telmisartan, Standard Blood Pressure Control
- Where
- 7 sites in United States
- Volunteers
- 558 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Polycystic Kidney, Type 1 Autosomal Dominant Disease
Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic hereditary kidney disease in humans. ADPKD may affect all the generations of the ADPKD family and the probability of ADPKD is 50% in the second…
- Trial name
- ESPERANCE (NCT02948179)
- Testing
- Preimplantation Genetic Diagnosis
- Where
- 31 sites in China
- Volunteers
- 459 people
- Sponsor
- Changlin Mei
Polycystic Kidney, Autosomal Dominant
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria.
- Trial name
- STOP-PKD (NCT07280585)
- Testing
- Dapagliflozin 10 mg
- Where
- 30 sites in Austria, Germany and 2 more
- Volunteers
- 420 people
- Sponsor
- University of Cologne
Polycystic Kidney Diseases
Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like protein) in the urine that is changed after treatment of hydralazine.
- Trial name
- NCT03423810
- Testing
- Hydralazine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Kansas Medical Center
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
A Phase 1 Study of Single and Multiple Ascending Doses of GV-100
This is a first-in-human, multi-part clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), food effect, and drug-drug interaction (DDI) potential of GV-100 following oral administration in healthy…
- Trial name
- NCT07788014
- Testing
- GV-100
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gilva Therapeutics Inc.
Polycystic Kidney Diseases, Polycystic Liver Disease
The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
Primary sarcopenia is used to describe aging and progressed with the physiologic decline. Secondary sarcopenia is associated many chronic disease, including acquired immune deficiency syndrome, cancer, chronic heart failure…
- Conditions
- Polycystic Kidney Diseases, Polycystic Liver Disease, Muscle Loss
- Trial name
- NCT05215964
- Testing
- Renal artery embolization
- Where
- Taiwan
- Volunteers
- 600 people
- Sponsor
- National Taiwan University Hospital
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease
The purpose of this study is to learn if dietary habits can affect vasopressin secretion in patients with autosomal dominant polycystic kidney disease.
- Trial name
- NCT02225860
- Testing
- Diet and water adjustment
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Tufts Medical Center
Polycystic Kidney, Autosomal Dominant
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
The purpose of this study is to evaluate the safety and effectiveness of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) in the real world clinical setting in Japan.
- Trial name
- NCT02847624
- Testing
- tolvaptan
- Where
- Japan
- Volunteers
- 1,802 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Polycystic Liver Disease
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
The purpose of the trial is to compare the effectiveness and safety of 2 treatment regimens of CAM2029 (given weekly or every 2 weeks) to placebo in participants with symptomatic PLD, either isolated as in autosomal dominant PLD…
- Trial name
- POSITANO (NCT05281328)
- Testing
- CAM2029
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 71 people
- Sponsor
- Camurus AB
Autosomal Dominant Polycystic Kidney Disease, Kidney Disease
New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease
The purpose of this study is to establish normal Magnetic Resonance quantitative values (tissues stiffness, Apparent Diffusion Coefficient values and Blood Oxygen Level Determination values for both renal cortex and medullary…
- Trial name
- MRI Pilot (NCT02250287)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects
This is a open-label, non-randomized, multiple oral dosings, three-period, drug-drug interaction study of JMKX003142 tablet, Amiodarone Hydrochloride Tablets and Febuxostat Tablets in Chinese healthy adult subjects
- Trial name
- NCT07181265
- Testing
- Amiodarone Hydrochloride Tablets, Febuxostat Tablets
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jemincare
Polycystic Kidney Disease, Adult
Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303
This is a Phase 3, open-label, roll-over study to demonstrate the continued hepatic and non-hepatic safety and renal efficacy of lixivaptan in participants with ADPKD who previously experienced abnormal liver chemistry test…
- Trial name
- NCT05208866
- Testing
- Lixivaptan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Palladio Biosciences
Liver Cyst, Polycystic Liver Disease
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts
Patients with large hepatic cysts (> 5cm) may develop symptoms. These can be captured with the polycystic liver disease questionnaire (PLD-Q).
- Conditions
- Liver Cyst, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney, Autosomal Dominant Polycystic Liver Disease
- Trial name
- ATLAS (NCT05500157)
- Testing
- aspiration sclerotherapy versus laparoscopic fenestration
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Radboud University Medical Center
Polycystic Liver Disease, Polycystic Kidney, Autosomal Dominant
Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
Rationale: Polycystic liver disease (PLD) is a rare disorder characterized by >20 fluid-filled hepatic cysts. Polycystic livers are present in the combination with renal cysts as a manifestation of autosomal dominant polycystic…
- Trial name
- CURSOR (NCT02021110)
- Testing
- Ursodeoxycholic Acid
- Where
- 3 sites in Netherlands, Spain
- Volunteers
- 34 people
- Sponsor
- Radboud University Medical Center
Polycystic Kidney, Autosomal Dominant
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The purpose of this study is to determine whether the medication pravastatin will ameliorate renal and cardiovascular disease over a 3-year period in children and young adults with autosomal dominant polycystic kidney disease…
- Trial name
- NCT00456365
- Testing
- pravastatin
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Colorado, Denver
ADPKD
The Vienna RAP Pilot Study
The purpose of this study is to evaluate the safety of a daily single oral dose of sirolimus in patients with advanced autosomal dominant polycystic kidney disease.
- Trial name
- RAP (NCT01632605)
- Testing
- Sirolimus
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Medical University of Vienna